Health & Nutrition
Ozempic (Semaglutide) and Other GLP-1 Weight-Loss Drugs:...
Ozempic and others in a new class of weight-loss drugs have been called “the medical...
Trump is unlikely to end Medicare drug price talks — here's...
Trump could either weaken the negotiations in a way that benefits the pharmaceutical...
Doximity shares pop 36% on revenue beat, rosy guidance
The company built a digital platform for medical professionals that can help them...
Hims & Hers faces scrutiny from senators on Super Bowl...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing...
Bristol Myers' stock decline in response to weak guidance...
The heart of our investment thesis in the drugmaker remains intact.
Alphabet's Verily to sell Granular insurance business to...
Alphabet's Verily is selling its subsidiary, Granular Insurance Company, to Elevance...
Doximity shares soar 25% after company beats on revenue,...
Doximity reported third-quarter fiscal 2025 results that beat analysts' expectations...
Novo Nordisk CEO says he's confident about Wegovy supply,...
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter...
Eli Lilly to release late-stage data on next-generation...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis...
Bristol Myers Squibb plans $2 billion in cost cuts by 2027,...
The company also issued a 2025 guidance that fell short of expectations, as some...
